Efficacy of MLN9708 (ixazomib) in experimental autoimmune myasthenia gravis and in anti-AChR producing primary thymic cell cultures from myasthenia gravis patients

Efficacy of MLN9708 (ixazomib) in experimental autoimmune myasthenia gravis and in anti-AChR producing primary thymic cell cultures from myasthenia gravis patients

Proteasome inhibitors can eliminate malignant, alloreactive, or autoreactive plasma cells. These cells are key players in antibody-mediated autoimmune disorders and thus suitable therapeutic targets for these drugs. However, certain proteasome inhibitors cause toxic peripheral neuropathy in patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Marina Mané-Damas, Abhishek Saxena, Gisela Nogales-Gadea, Jo Stevens, Shannen Vincken, Maarten van Beek, Nynke J. van den Hoogen, Elbert A. J. Joosten, Nick Willcox, Hans Duimel, Jos G. Maessen, Peter C. Molenaar, Marc H. De Baets, Mario Losen, Pilar Martinez-Martinez
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Immunology
Subjects:
ixazomib
targeting autoimmune plasma cells
myasthenia gravis
proteasome inhibition
autoantibody
therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1521432/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1521432/full

Similar Items